Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5 | P01031 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 13/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568048 | 0.99 | C5 (0.53) | C5FAAHPPARAMEN1KMT2A | |
| SCHEMBL6566667 | 0.90 | RAB9A (0.52) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6566206 | 0.87 | MEN1 (0.47) | C5MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6566981 | 0.86 | NOX1 (0.53) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL6568011 | 0.86 | KDM4E (0.54) | MEN1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL6564786 | 0.85 | KMT2A (0.61) | MEN1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL6566525 | 0.85 | SMN1; SMN2 (0.52) | MEN1KMT2ALMNASMN1; SMN2CA12 | |
| SCHEMBL6565846 | 0.85 | MEN1 (0.52) | MEN1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL6567665 | 0.84 | CASR (0.56) | C5MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6566741 | 0.83 | MEN1 (0.52) | MEN1KMT2ALMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | C5 2265/4885FAAH 505/4885PPARA 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.